The Servier group is confident. The results of its 2021-2022 financial year, ending on September 30, 2022,confirms the group’s transformation trajectory“, judged Olivier Laureau, the president of the French laboratory, during an online presentation organized Thursday, February 2. At constant exchange rates, Servier’s turnover increased by 6.6%, reaching 4.88 billion euros, for an Ebitda up by 34.6%, at 859 million euros, and a result went from a net loss of 95 million euros the previous year, to a net profit of 192 million euros. At the heart of this assessment, the group is satisfied first and foremost with the progress of its oncology franchise, which has become its strategic priority ahead of the cardio-metabolism/venous diseases division and that of generic drugs. Oncology posted sales up nearly 35%, to 848 million euros, with staggered sales targets of 1 billion euros in 2025 then 3 billion in 2030, when Servier is aiming for global sales of around 8 billion euros.
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Login
VOS INDICES
source
Selected for you
